Actively Recruiting

Age: 18Years +
All Genders
ID07468058

Diabetic Retinopathy Prevalence And Risk Factors From A Hospital-Based Cohort In Central Vietnam

Led by Da Nang Family General Hospital · Updated on 2026-03-12

300

Participants Needed

1

Research Sites

2 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Diabetic retinopathy (DR) is a common cause of preventable vision loss globally, affecting about 22-26% of people with diabetes, with vision-threatening cases in about 6%. This research aims to determine the local prevalence, severity, and risk factors of DR among diabetic patients at Gia Dinh Family Hospital in Da Nang, Vietnam. Understanding these factors is important to improve screening and management to reduce vision loss in this population. The study observes diabetic patients who have undergone eye examinations including dilated fundus examination and optical coherence tomography (OCT) during the period from January to September 2025. These patients are identified through the hospital's electronic health records. No treatments are given; the study collects and reviews clinical and laboratory data from medical records to analyze DR prevalence and associated risk factors. Participants will have had their eye exams and medical records reviewed for diabetes diagnosis and key health information. Researchers will measure how common DR is, at what stages it occurs, and which health factors are linked to DR presence. The main outcome is the prevalence of any stage of DR at baseline. The study will conclude by March 2026, with data collected retrospectively from the 2025 study period.

CONDITIONS

Brief Title

Diabetic Retinopathy Prevalence And Risk Factors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed diabetes mellitus (type 1 or type 2) according to ADA criteria
  • Underwent ophthalmic examination including dilated fundus examination and OCT
  • Available electronic medical records with key clinical and laboratory data
Not Eligible

You will not qualify if you...

  • Gestational diabetes mellitus
  • Media opacity precluding fundus examination (advanced cataract, corneal opacity, dense vitreous hemorrhage)
  • Other retinal diseases (e.g., hypertensive retinopathy, retinal vein occlusion)
  • History of ocular trauma or intraocular surgery within 6 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Baseline during study period January to September 2025

Participants undergo ophthalmologic examinations including dilated fundus examination and optical coherence tomography (OCT) to assess diabetic retinopathy presence and severity.

1 visit (in-person)

Long-term Monitoring

Duration - Up to approximately 6 months following baseline assessment

Participants are observed through electronic medical records to evaluate risk factors and outcomes related to diabetic retinopathy.

No additional visits; data collected from routine care records

Trial Site Locations

Total: 1 location

1

Department of Endocrinology and Diabetes

Da Nang, Vietnam, 50000

Actively Recruiting

Loading map...

Research Team

T

Thảo Nguyễn, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Artificial Intelligence-Aided Screening for Patients With Di...

Age-Related Macular Degeneration (AMD)

Actively Recruiting

1 location

Assessment of DRISTi as an Automated Diabetic Retinopathy Sc...

Diabetic Retinopathy (DR)

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here